DafinchiIncrease in HCP Prescriptions for MYCorzo During 2026 Q1 to April
The number of healthcare professionals prescribing MYCorzo significantly increased from the end of Q1 to April 2026, indicating expanded adoption.
Read post
Detailed company information
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 06, 2026
Earnings Transcript for 2026 - Q1Released: May 05, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Nov 06, 2025
Earnings Transcript for 2025 - Q2Released: Aug 08, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 06, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 03, 2023
Earnings Transcript for 2023 - Q2Released: Aug 03, 2023
Earnings Transcript for 2023 - Q1Released: May 04, 2023
Earnings Transcript for 2022 - Q4Released: Mar 01, 2023
Earnings Transcript for 2022 - Q3Released: Nov 06, 2022
Earnings Transcript for 2022 - Q2Released: Aug 07, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Feb 25, 2022
Earnings Transcript for 2021 - Q3Released: Nov 04, 2021
Earnings Transcript for 2021 - Q2Released: Aug 05, 2021
Earnings Transcript for 2021 - Q1Released: May 07, 2021
Earnings Transcript for 2020 - Q4Released: Feb 26, 2021
Earnings Transcript for 2020 - Q3Released: Nov 04, 2020
Earnings Transcript for 2020 - Q2Released: Aug 06, 2020
STOK Stoke Therapeutics, Inc.
DYN Dyne Therapeutics, Inc.
EWTX Edgewise Therapeutics, Inc.
RLAY Relay Therapeutics, Inc.
ARVN Arvinas, Inc.
RVMD Revolution Medicines, Inc.
AMLX Amylyx Pharmaceuticals, Inc.
KNSA Kiniksa Pharmaceuticals International, plc
COGT Cogent Biosciences, Inc.
KROS Keros Therapeutics, Inc.
NBIX Neurocrine Biosciences, Inc.
EXEL Exelixis, Inc.
The number of healthcare professionals prescribing MYCorzo significantly increased from the end of Q1 to April 2026, indicating expanded adoption.
Read post